Replies to post #28237 on OncoSec Medical Inc (ONCSQ)

[cameron12x]

Leading biotech companies may disagree with you.

Amgen purchased T-VEC from Biovex for $425M cash up front with milestone incentives totaling $1B in 2011:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109088921

The efficacy and safety profile for T-VEC as a monotherapy was similar, but not quite as good as ONCS' ImmunoPulse.

The recent T-VEC/Yervoy combination results are very good and there is much excitement around the ImmunoPulse/Keytruda PD1 combination which may offer even better efficacy without side effects.

Why would you not be excited about such a combination? Clearly, leading experts in the field of oncology and immunology are. What technology interests you more and why?

[twiz0019]

Please explain why you say that the science & data are not very promising? Who has had better results in Melanoma? They have shown FIFTY % systemic results...how can you say that's not promising???